Filing Details
- Accession Number:
- 0000950170-24-007032
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-24 17:00:05
- Reporting Period:
- 2024-01-22
- Accepted Time:
- 2024-01-24 17:00:05
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1789972 | Cullinan Oncology Inc. | CGEM | Biological Products, (No Disgnostic Substances) (2836) | 813867811 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1837524 | Corrine Savill | C/O Cullinan Oncology, Inc. One Main Street, Suite 1350 Cambridge MA 02142 | Chief Business Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-22 | 14,559 | $4.30 | 184,674 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-22 | 14,559 | $12.18 | 170,115 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-01-22 | 4,125 | $12.02 | 165,990 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-01-23 | 21,316 | $4.30 | 187,306 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-23 | 21,316 | $12.46 | 165,990 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-01-22 | 14,559 | $0.00 | 14,559 | $4.30 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-01-23 | 21,316 | $0.00 | 21,316 | $4.30 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 35,313 | 2030-10-28 | No | 4 | M | Direct | |
| 13,997 | 2030-10-28 | No | 4 | M | Direct |
Footnotes
- Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.44. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.16 to $12.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023.
Billionaire Hedge Funds
